An Adolescent Patient With Idiopathic Pulmonary Arterial Hypertension Weaned Off Intravenous Epoprostenol Following Treatment With Selexipag: A Case Report

An Adolescent Patient With Idiopathic Pulmonary Arterial Hypertension Weaned Off Intravenous Epoprostenol Following Treatment With Selexipag: A Case Report

Idiopathic pulmonary arterial hypertension (PAH) is a rare, progressive disease affecting the pulmonary arteries. Epoprostenol, a synthetic prostaglandin analog, is the most potent pharmacological treatment modality used in patients with PAH. However, it requires continuous intravenous infusion, whi...

Full description

Bibliographic Details
Main Authors: Ayako Chida-Nagai, Takao Tsujioka, Daisuke Sasaki, Gaku Izumi, Hirokuni Yamazawa, Atsuhito Takeda
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Pediatrics
Subjects:
pulmonary arterial hypertension
epoprostenol
drug transition
adolescence
selexipag
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2022.909595/full

Internet

https://www.frontiersin.org/articles/10.3389/fped.2022.909595/full

Similar Items